Analysts and investors focused on the apparent lack of synergy behind AstraZeneca and Ionis’ knockdown-and-stabilizer strategy after the Phase 3 fizzle in transthyretin amyloid cardiomyopathy. Reporting framed the Cardio-TTRansform outcome as a sign that the intended combination approach was “dead,” according to an expert cited in the coverage. Despite substantial reductions in transthyretin (TTR) levels, the trial failed to hit the composite endpoint of reducing cardiovascular mortality and recurrent cardiovascular events. The combination question now affects how teams evaluate knockdown agents with stabilizers in the clinic. Market attention is likely to pivot to whether future ATTR-CM regimens can demonstrate event-driven clinical benefit beyond biomarker lowering, while also considering how trial endpoints and patient selection influence perceived efficacy.